Lawrence Young, MD
Research & Publications
Biography
News
Research Summary
Our laboratory is studying the cellular and molecular mechanisms responsible for the metabolic adaptation to the hypoxic stress associated with myocardial ischemia.
Specialized Terms: Myocardial ischemia; Metabolic adaptation to hypoxic stress; Cardio-protection; Cardiomyopathy; LKB1-AMPK pathway; Diabetes
Extensive Research Description
Our laboratory is studying the cellular and molecular mechanisms responsible for the metabolic adaptation to the hypoxic stress associated with myocardial ischemia, recently focusing on the AMP-activated protein kinase (AMPK) signaling pathway. AMPK has emerged as a key regulator of glucose transporter (GLUT4) translocation, cellular metabolism, ion channel activity, and cell survival and apoptosis in the heart.
Combining physiologic models of ischemia with cellular and molecular techniques, we are interested in the cardio-protective action of AMPK in the heart, the upstream mechanisms of AMPK activation and its downstream interaction with other signaling pathways, as well as the discovery of novel AMPK targets. The use of transgenic mouse models allows us to dissect the role of AMPK and other signaling pathways in the intact perfused heart and in vivo. The goal of this research is to develop novel strategies to protect the heart against injury during myocardial ischemia.
- Stress signaling pathways is the heart.
- Alterations in metabolism in cardiac disease.
- AMPK as a target for protecting the heart against ischemic injury.
- LKB1 regulation of metabolic signaling and cardic growth.
- Cardiac-derived autocrine-paracrine secreted proteins in the regulation of cardiac signaling pathways.
- Insulin resistance and diabetes in cardiovascular disease.
Coauthors
Research Interests
Cell Survival; Diabetes Mellitus; Insulin Resistance; Myocardial Ischemia; Apoptosis; Glucose Transporter Type 4; AMP-Activated Protein Kinases
Selected Publications
- Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome.Yang B, Huang Y, Zhang H, Huang Y, Zhou HJ, Young L, Xiao H, Min W. Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome. Journal Of Molecular And Cellular Cardiology 2020, 138:291-303.
- Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations.Kim AS, Henderson KJ, Pawar S, Kim MJ, Punjani S, Pollak JS, Fahey JT, Garcia-Tsao G, Sugeng L, Young LH. Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations. Journal Of The American Heart Association 2020, 9:e016197.
- Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease.Dearborn JL, Viscoli CM, Inzucchi SE, Young LH, Kernan WN. Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. International Journal Of Stroke : Official Journal Of The International Stroke Society 2019, 14:639-645.
- Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.Spence JD, Viscoli CM, Inzucchi SE, Dearborn-Tomazos J, Ford GA, Gorman M, Furie KL, Lovejoy AM, Young LH, Kernan WN. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurology 2019, 76:526-535.
- Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity.Dearborn JL, Viscoli CM, Young LH, Gorman MJ, Furie KL, Kernan WN. Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. Stroke; A Journal Of Cerebral Circulation 2019, 50:713-717.
- Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.Pfau D, Thorn SL, Zhang J, Mikush N, Renaud JM, Klein R, deKemp RA, Wu X, Hu X, Sinusas AJ, Young LH, Tirziu D. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Scientific Reports 2019, 9:5791.
- Presentation of Liver Failure From a Pericardial Mass.Nguyen VQ, Workman V, Stendahl K, Young L, Sklar J, Baldassarre LA. Presentation of Liver Failure From a Pericardial Mass. Circulation. Cardiovascular Imaging 2019, 12:e008672.
- GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance.Luan H, Wang A, Hilliard B, Carvalho F, Rosen C, Ahasic A, Herzog E, Kang I, Pisani M, Yu S, Zhang C, Ring A, Young L, Medzhitov R. GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance. Cell 2019, 178:1231-1244.e11.
- Cardiomyocyte d-dopachrome tautomerase protects against heart failure.Ma Y, Su KN, Pfau D, Rao VS, Wu X, Hu X, Leng L, Du X, Piecychna M, Bedi K, Campbell SG, Eichmann A, Testani JM, Margulies KB, Bucala R, Young LH. Cardiomyocyte d-dopachrome tautomerase protects against heart failure. JCI Insight 2019, 4.
- Diabetes prevention and cardiovascular complications.Inzucchi SE, Viscoli CM, Young LH, Kernan WN. Diabetes prevention and cardiovascular complications. Diabetologia 2019, 62:2161-2162.
- Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.Furie KL, Viscoli CM, Gorman M, Ford GA, Young LH, Inzucchi SE, Guarino PD, Lovejoy AM, Conwit R, Tanne D, Kernan WN. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. Journal Of Neurology, Neurosurgery, And Psychiatry 2018, 89:21-27.
- Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, Young LH, Inzucchi SE, Lovejoy AM, Kasner SE, Conwit R, Kernan WN. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Circulation 2018, 137:455-463.
- AMP-activated protein kinase and adenosine are both metabolic modulators that regulate chloride secretion in the shark rectal gland ( Squalus acanthias).Neuman RI, van Kalmthout JAM, Pfau DJ, Menendez DM, Young LH, Forrest JN. AMP-activated protein kinase and adenosine are both metabolic modulators that regulate chloride secretion in the shark rectal gland ( Squalus acanthias). American Journal Of Physiology. Cell Physiology 2018, 314:C473-C482.
- Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia.Haghighat L, Brandt EJ, Proctor DD, Garcia-Tsao G, Pollak J, Young L. Evolution of Intrahepatic Shunts in a Patient With Hereditary Hemorrhagic Telangiectasia. Annals Of Internal Medicine 2018, 169:508-509.
- Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138:1210-1220.
- Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation.Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, Herzog RI, Young LH, Qian L, Hwa J, Xiang Y. Diabetes Exacerbates Myocardial Ischemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation of O-GlcNAcylation. JACC. Basic To Translational Science 2018, 3:350-362.
- In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents.Boutagy NE, Wu J, Cai Z, Zhang W, Booth CJ, Kyriakides TC, Pfau D, Mulnix T, Liu Z, Miller EJ, Young LH, Carson RE, Huang Y, Liu C, Sinusas AJ. In Vivo Reactive Oxygen Species Detection With a Novel Positron Emission Tomography Tracer, 18F-DHMT, Allows for Early Detection of Anthracycline-Induced Cardiotoxicity in Rodents. JACC. Basic To Translational Science 2018, 3:378-390.
- Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.Cui D, Peng Y, Zhang C, Li Z, Su Y, Qi Y, Xing M, Li J, Kim GE, Su KN, Xu J, Wang M, Ding W, Piecychna M, Leng L, Hirasawa M, Jiang K, Young L, Xu Y, Qi D, Bucala R. Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy. The Journal Of Clinical Investigation 2018, 128:4997-5007.
- Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk.Viscoli CM, Kent DM, Conwit R, Dearborn JL, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH, Kernan WN. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke; A Journal Of Cerebral Circulation 2018, STROKEAHA118022745.
- Pioglitazone and cardiovascular risk reduction: time for a second look?Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovascular Endocrinol 2017;6:55-61
- Smoking cessation and outcome after ischemic stroke or TIA.Epstein KA, Viscoli CM, Spence JD, Young LH, Inzucchi SE, Gorman M, Gerstenhaber B, Guarino PD, Dixit A, Furie KL, Kernan WN. Smoking cessation and outcome after ischemic stroke or TIA. Neurology 2017, 89:1723-1729.
- Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".Young LH, Viscoli CM, Inzucchi SE, Kernan WN. Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". Circulation 2017, 136:1567-1568.
- Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology 2017, 74:1319-1327.
- MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics.Tilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opinion On Therapeutic Targets 2017, 21:671-683.
- Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. Diabetes Care 2017, 40:e47-e48.
- Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. The Journal Of Clinical Endocrinology And Metabolism 2017, 102:914-922.
- Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations.Chizinga M, Rudkovskaia AA, Henderson K, Pollak J, Garcia-Tsao G, Young LH, Fares WH. Pulmonary Hypertension Prevalence and Prognosis in a Cohort of Patients with Hereditary Hemorrhagic Telangiectasia Undergoing Embolization of Pulmonary Arteriovenous Malformations. American Journal Of Respiratory And Critical Care Medicine 2017, 196:1353-1356.
- Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit RA, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Circulation 2017, 135:1882-1893.
- Pioglitazone and cardiovascular risk reduction: time for a second look?Perdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction: time for a second look? Cardiovascular Endocrinology 2017, 6:55-61.
- ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction.Bartulos O, Zhuang ZW, Huang Y, Mikush N, Suh C, Bregasi A, Wang L, Chang W, Krause DS, Young LH, Pober JS, Qyang Y. ISL1 cardiovascular progenitor cells for cardiac repair after myocardial infarction. JCI Insight 2016, 1.
- miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart.Li N, Hwangbo C, Jaba IM, Zhang J, Papangeli I, Han J, Mikush N, Larrivée B, Eichmann A, Chun HJ, Young LH, Tirziu D. miR-182 Modulates Myocardial Hypertrophic Response Induced by Angiogenesis in Heart. Scientific Reports 2016, 6:21228.
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.Viscoli CM, Kernan WN, Young LH. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. The New England Journal Of Medicine 2016, 375:704.
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. The New England Journal Of Medicine 2016, 374:1321-31.
- AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia.Zaha VG, Qi D, Su KN, Palmeri M, Lee HY, Hu X, Wu X, Shulman GI, Rabinovitch PS, Russell RR, Young LH. AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia. Journal Of Molecular And Cellular Cardiology 2016, 91:104-13.
- Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, Pratley RE, Schwartz GG, Kernan WN. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016, 39:1684-92.
- PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia.Ola R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, Hirschi KK, Sessa WC, Canals FV, Graupera M, Yan M, Young LH, Oh PS, Eichmann A. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nature Communications 2016, 7:13650.
- Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study.Chyun DA, Wackers FJ, Inzucchi SE, Jose P, Weiss C, Davey JA, Heller GV, Iskandrian AE, Young LH. Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. SAGE Open Medicine 2015, 3:2050312114568476.
- AMPK and the Atrial Response to Metabolic Inhibition.Kim GE, Young LH. AMPK and the Atrial Response to Metabolic Inhibition. Journal Of The American College Of Cardiology 2015, 66:59-61.
- AMPK: energy sensor and survival mechanism in the ischemic heart.Qi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic heart. Trends In Endocrinology And Metabolism: TEM 2015, 26:422-9.
- LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.Kim GE, Ross JL, Xie C, Su KN, Zaha VG, Wu X, Palmeri M, Ashraf M, Akar JG, Russell KS, Akar FG, Young LH. LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation. Cardiovascular Research 2015, 108:197-208.
- The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury.Qi D, Atsina K, Qu L, Hu X, Wu X, Xu B, Piecychna M, Leng L, Fingerle-Rowson G, Zhang J, Bucala R, Young LH. The vestigial enzyme D-dopachrome tautomerase protects the heart against ischemic injury. The Journal Of Clinical Investigation 2014, 124:3540-50.
- Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Lovejoy AM, Parsons MW, Peduzzi PN, Ringleb PA, Schwartz GG, Spence JD, Tanne D, Young LH, Kernan WN. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. American Heart Journal 2014, 168:823-9.e6.
- Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.Young LH, Henderson KJ, White RI, Garcia-Tsao G. Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia. Hepatology (Baltimore, Md.) 2013, 58:442-5.
- Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction.Wang J, Tong C, Yan X, Yeung E, Gandavadi S, Hare AA, Du X, Chen Y, Xiong H, Ma C, Leng L, Young LH, Jorgensen WL, Li J, Bucala R. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation 2013, 128:225-36.
- Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart.Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L, Sherwin RS, Young LH. Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110:16133-8.
- The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes.Hage FG, Wackers FJ, Bansal S, Chyun DA, Young LH, Inzucchi SE, Iskandrian AE. The heart rate response to adenosine: a simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. International Journal Of Cardiology 2013, 167:2952-7.
- NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.Jaba IM, Zhuang ZW, Li N, Jiang Y, Martin KA, Sinusas AJ, Papademetris X, Simons M, Sessa WC, Young LH, Tirziu D. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. The Journal Of Clinical Investigation 2013, 123:1718-31.
- Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation.Shugrue CA, Alexandre M, Diaz de Villalvilla A, Kolodecik TR, Young LH, Gorelick FS, Thrower EC. Cerulein hyperstimulation decreases AMP-activated protein kinase levels at the site of maximal zymogen activation. American Journal Of Physiology. Gastrointestinal And Liver Physiology 2012, 303:G723-32.
- AMP-activated protein kinase regulation and biological actions in the heart.Zaha VG, Young LH. AMP-activated protein kinase regulation and biological actions in the heart. Circulation Research 2012, 111:800-14.
- Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study.Tandon S, Wackers FJ, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH. Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study. Diabetes & Vascular Disease Research 2012, 9:124-30.
- AMP-activated protein kinase (AMPK) activation and glycogen synthase kinase-3β (GSK-3β) inhibition induce Ca2+-independent deposition of tight junction components at the plasma membrane.Zhang L, Jouret F, Rinehart J, Sfakianos J, Mellman I, Lifton RP, Young LH, Caplan MJ. AMP-activated protein kinase (AMPK) activation and glycogen synthase kinase-3β (GSK-3β) inhibition induce Ca2+-independent deposition of tight junction components at the plasma membrane. The Journal Of Biological Chemistry 2011, 286:16879-90.
- A small molecule AMPK activator protects the heart against ischemia-reperfusion injury.Kim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K, Young LH. A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. Journal Of Molecular And Cellular Cardiology 2011, 51:24-32.
- Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysis.Bansal S, Wackers FJ, Inzucchi SE, Chyun DA, Davey JA, Staib LH, Young LH. Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysis. Diabetes Care 2011, 34:204-9.
- International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.Faughnan ME, Palda VA, Garcia-Tsao G, Geisthoff UW, McDonald J, Proctor DD, Spears J, Brown DH, Buscarini E, Chesnutt MS, Cottin V, Ganguly A, Gossage JR, Guttmacher AE, Hyland RH, Kennedy SJ, Korzenik J, Mager JJ, Ozanne AP, Piccirillo JF, Picus D, Plauchu H, Porteous ME, Pyeritz RE, Ross DA, Sabba C, Swanson K, Terry P, Wallace MC, Westermann CJ, White RI, Young LH, Zarrabeitia R. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal Of Medical Genetics 2011, 48:73-87.
- Risk stratification in diabetes: not all patients or perfusion defects are the same.Young LH. Risk stratification in diabetes: not all patients or perfusion defects are the same. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2010, 17:990-2.
- Diet-induced obesity obstructs insulin signaling in the heart.Young LH. Diet-induced obesity obstructs insulin signaling in the heart. American Journal Of Physiology. Heart And Circulatory Physiology 2010, 298:H306-7.
- Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion.Qi D, Hu X, Wu X, Merk M, Leng L, Bucala R, Young LH. Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. The Journal Of Clinical Investigation 2009, 119:3807-16.
- Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs).Kernan WN, Viscoli CM, Demarco D, Mendes B, Shrauger K, Schindler JL, McVeety JC, Sicklick A, Moalli D, Greco P, Bravata DM, Eisen S, Resor L, Sena K, Story D, Brass LM, Furie KL, Gutmann L, Hinnau E, Gorman M, Lovejoy AM, Inzucchi SE, Young LH, Horwitz RI. Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs). Neurology 2009, 72:1345-51.
- Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial.Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009, 301:1547-55.
- A crystallized view of AMPK activation.Young LH. A crystallized view of AMPK activation. Cell Metabolism 2009, 10:5-6.
- Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) study.Wackers FJ, Young LH. Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) study. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2009, 16:855-9.
- AMP-activated protein kinase: a core signalling pathway in the heart.Kim AS, Miller EJ, Young LH. AMP-activated protein kinase: a core signalling pathway in the heart. Acta Physiologica (Oxford, England) 2009, 196:37-53.
- The pulmonary vascular complications of hereditary haemorrhagic telangiectasia.Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. The European Respiratory Journal 2009, 33:1186-94.
- AMP-activated protein kinase conducts the ischemic stress response orchestra.Young LH. AMP-activated protein kinase conducts the ischemic stress response orchestra. Circulation 2008, 117:832-40.
- Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart.Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R, Young LH. Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008, 451:578-82.
- Infusion of a biotinylated bis-glucose photolabel: a new method to quantify cell surface GLUT4 in the intact mouse heart.Miller EJ, Li J, Sinusas KM, Holman GD, Young LH. Infusion of a biotinylated bis-glucose photolabel: a new method to quantify cell surface GLUT4 in the intact mouse heart. American Journal Of Physiology. Endocrinology And Metabolism 2007, 292:E1922-8.
- Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study.Wackers FJ, Chyun DA, Young LH, Heller GV, Iskandrian AE, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007, 30:2892-8.
- Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis.Reznick RM, Zong H, Li J, Morino K, Moore IK, Yu HJ, Liu ZX, Dong J, Mustard KJ, Hawley SA, Befroy D, Pypaert M, Hardie DG, Young LH, Shulman GI. Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metabolism 2007, 5:151-6.
- Insulin sensitivity, vascular function, and iron stores in voluntary blood donors.Zheng H, Patel M, Cable R, Young L, Katz SD. Insulin sensitivity, vascular function, and iron stores in voluntary blood donors. Diabetes Care 2007, 30:2685-9.
- Screening for coronary artery disease in patients with diabetes.Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007, 30:2729-36.
- Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart.Li J, Coven DL, Miller EJ, Hu X, Young ME, Carling D, Sinusas AJ, Young LH. Activation of AMPK alpha- and gamma-isoform complexes in the intact ischemic rat heart. American Journal Of Physiology. Heart And Circulatory Physiology 2006, 291:H1927-34.
- Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging.Papaioannou GI, Kasapis C, Seip RL, Grey NJ, Katten D, Wackers FJ, Inzucchi SE, Engel S, Taylor A, Young LH, Chyun DA, Davey JA, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Heller GV. Value of peripheral vascular endothelial function in the detection of relative myocardial ischemia in asymptomatic type 2 diabetic patients who underwent myocardial perfusion imaging. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2006, 13:362-8.
- AMP-activated protein kinase regulates the assembly of epithelial tight junctions.Zhang L, Li J, Young LH, Caplan MJ. AMP-activated protein kinase regulates the assembly of epithelial tight junctions. Proceedings Of The National Academy Of Sciences Of The United States Of America 2006, 103:17272-7.
- Diabetes mellitus and cardiovascular disease.Chyun DA, Young LH. Diabetes mellitus and cardiovascular disease. The Nursing Clinics Of North America 2006, 41:681-95, viii-ix.
- AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart.Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR, Young LH. AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circulation Research 2005, 97:872-9.
- AMP-activated protein kinase: a key stress signaling pathway in the heart.Young LH, Li J, Baron SJ, Russell RR. AMP-activated protein kinase: a key stress signaling pathway in the heart. Trends In Cardiovascular Medicine 2005, 15:110-8.
- Dual mechanisms regulating AMPK kinase action in the ischemic heart.Baron SJ, Li J, Russell RR, Neumann D, Miller EJ, Tuerk R, Wallimann T, Hurley RL, Witters LA, Young LH. Dual mechanisms regulating AMPK kinase action in the ischemic heart. Circulation Research 2005, 96:337-45.
- Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome.Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. Metabolic Syndrome And Related Disorders 2005, 3:147-73.
- AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury.Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. The Journal Of Clinical Investigation 2004, 114:495-503.
- Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle.Li J, Hu X, Selvakumar P, Russell RR, Cushman SW, Holman GD, Young LH. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. American Journal Of Physiology. Endocrinology And Metabolism 2004, 287:E834-41.
- Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study).Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). The American Journal Of Cardiology 2004, 94:294-9.
- Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study.Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Wittlin SD, Heller GV, Filipchuk N, Engel S, Ratner RE, Iskandrian AE. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004, 27:1954-61.
- Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart.Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, Johnson RS, Giordano FJ. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB Journal : Official Publication Of The Federation Of American Societies For Experimental Biology 2004, 18:1138-40.
- Diastolic function and type 1 diabetes.Young LH. Diastolic function and type 1 diabetes. Diabetes Care 2004, 27:2081-3.
- Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, Chyun DA, Law G, Wackers FJ, Young LH. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 2004, 27:448-54.
- Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-63.
- Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise.Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, Young LH. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. American Journal Of Physiology. Endocrinology And Metabolism 2003, 285:E629-36.
- Diagnosis of CAD in patients with diabetes: who to evaluate.Young LH, Jose P, Chyun D. Diagnosis of CAD in patients with diabetes: who to evaluate. Current Diabetes Reports 2003, 3:19-27.
- Insulin resistance and the effects of thiazolidinediones on cardiac metabolism.Young LH. Insulin resistance and the effects of thiazolidinediones on cardiac metabolism. The American Journal Of Medicine 2003, 115 Suppl 8A:75S-80S.
- Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108:2941-8.
- Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia.Shi CQ, Young LH, Daher E, DiBella EV, Liu YH, Heller EN, Zoghbi S, Wackers FJ, Soufer R, Sinusas AJ. Correlation of myocardial p-(123)I-iodophenylpentadecanoic acid retention with (18)F-FDG accumulation during experimental low-flow ischemia. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2002, 43:421-31.
- AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation.Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99:15983-7.
- Cardiac outcomes after myocardial infarction in elderly patients with diabetes mellitus.Chyun D, Vaccarino V, Murillo J, Young LH, Krumholz HM. Cardiac outcomes after myocardial infarction in elderly patients with diabetes mellitus. American Journal Of Critical Care : An Official Publication, American Association Of Critical-Care Nurses 2002, 11:504-19.
- Acute myocardial infarction in the elderly with diabetes.Chyun D, Vaccarino V, Murillo J, Young LH, Krumholz HM. Acute myocardial infarction in the elderly with diabetes. Heart & Lung : The Journal Of Critical Care 2002, 31:327-39.
- Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patients.Russell RR, Chyun D, Song S, Sherwin RS, Tamborlane WV, Lee FA, Pfeifer MA, Rife F, Wackers FJ, Young LH. Cardiac responses to insulin-induced hypoglycemia in nondiabetic and intensively treated type 1 diabetic patients. American Journal Of Physiology. Endocrinology And Metabolism 2001, 281:E1029-36.
- Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis.Bergeron R, Ren JM, Cadman KS, Moore IK, Perret P, Pypaert M, Young LH, Semenkovich CF, Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. American Journal Of Physiology. Endocrinology And Metabolism 2001, 281:E1340-6.
- Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.Bergeron R, Previs SF, Cline GW, Perret P, Russell RR, Young LH, Shulman GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001, 50:1076-82.
- Cellular and molecular regulation of cardiac glucose transport.Young LH, Coven DL, Russell RR. Cellular and molecular regulation of cardiac glucose transport. Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 2000, 7:267-76.
- Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease.McNulty PH, Jacob R, Deckelbaum LI, Young LH. Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism: Clinical And Experimental 2000, 49:1365-9.
- Liver disease in patients with hereditary hemorrhagic telangiectasia.Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Jain D, Byrd B, Pollak JS, White RI. Liver disease in patients with hereditary hemorrhagic telangiectasia. The New England Journal Of Medicine 2000, 343:931-6.
- Regulation of myocardial glucose uptake and transport during ischemia and energetic stress.Young LH, Russell RR, Yin R, Caplan MJ, Ren J, Bergeron R, Shulman GI, Sinusas AJ. Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. The American Journal Of Cardiology 1999, 83:25H-30H.
- Insulin-like growth factor I stimulates cardiac myosin heavy chain and actin synthesis in the awake rat.Young LH, Renfu Y, Hu X, Chong S, Hasan S, Jacob R, Sherwin RS. Insulin-like growth factor I stimulates cardiac myosin heavy chain and actin synthesis in the awake rat. The American Journal Of Physiology 1999, 276:E143-50.
- Effect of AMPK activation on muscle glucose metabolism in conscious rats.Bergeron R, Russell RR, Young LH, Ren JM, Marcucci M, Lee A, Shulman GI. Effect of AMPK activation on muscle glucose metabolism in conscious rats. The American Journal Of Physiology 1999, 276:E938-44.
- Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR.Russell RR, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. The American Journal Of Physiology 1999, 277:H643-9.
- Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo.Russell RR, Yin R, Caplan MJ, Hu X, Ren J, Shulman GI, Sinusas AJ, Young LH. Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation 1998, 98:2180-6.
- Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo.Young LH, Renfu Y, Russell R, Hu X, Caplan M, Ren J, Shulman GI, Sinusas AJ. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997, 95:415-22.
- Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia.McNulty PH, Sinusas AJ, Shi CQ, Dione D, Young LH, Cline GC, Shulman GI. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. The Journal Of Clinical Investigation 1996, 98:62-9.
- IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids.Jacob R, Hu X, Niederstock D, Hasan S, McNulty PH, Sherwin RS, Young LH. IGF-I stimulation of muscle protein synthesis in the awake rat: permissive role of insulin and amino acids. The American Journal Of Physiology 1996, 270:E60-6.
- Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance.McNulty PH, Louard RJ, Deckelbaum LI, Zaret BL, Young LH. Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance. Circulation 1995, 92:2151-6.
- Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia.Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, Rinker BD, Wackers FJ, Zaret BL. Technetium-99m-nitroimidazole (BMS181321): a positive imaging agent for detecting myocardial ischemia. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 1995, 36:1078-86.
- Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis in vivo.Young LH, Stirewalt W, McNulty PH, Revkin JH, Barrett EJ. Effect of insulin on rat heart and skeletal muscle phenylalanyl-tRNA labeling and protein synthesis in vivo. The American Journal Of Physiology 1994, 267:E337-42.
- Metabolic imaging: what are the challenges?Young LH, McNulty PH. Metabolic imaging: what are the challenges? Journal Of Nuclear Cardiology : Official Publication Of The American Society Of Nuclear Cardiology 1994, 1:213-7.
- Response of rat heart and skeletal muscle protein in vivo to insulin and amino acid infusion.McNulty PH, Young LH, Barrett EJ. Response of rat heart and skeletal muscle protein in vivo to insulin and amino acid infusion. The American Journal Of Physiology 1993, 264:E958-65.
- Protein synthesis in pulmonary arteries from rats exposed to hyperoxia.Stirewalt WS, Coflesky JT, Young LH, Evans JN. Protein synthesis in pulmonary arteries from rats exposed to hyperoxia. The American Journal Of Physiology 1993, 264:L74-9.
- Physiological hyperinsulinemia inhibits myocardial protein degradation in vivo in the canine heart.Young LH, Dahl DM, Rauner D, Barrett EJ. Physiological hyperinsulinemia inhibits myocardial protein degradation in vivo in the canine heart. Circulation Research 1992, 71:393-400.
- Equine arch vessel anomaly associated with coarctation of the aorta.Hoch DH, Salazar AM, Cabin HS, Young LH. Equine arch vessel anomaly associated with coarctation of the aorta. Chest 1992, 102:634-5.
- Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion.Young LH, McNulty PH, Morgan C, Deckelbaum LI, Zaret BL, Barrett EJ. Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion. The Journal Of Clinical Investigation 1991, 87:554-60.
- In vivo measurement of myocardial protein turnover using an indicator dilution technique.Revkin JH, Young LH, Stirewalt WS, Dahl DM, Gelfand RA, Zaret BL, Barrett EJ. In vivo measurement of myocardial protein turnover using an indicator dilution technique. Circulation Research 1990, 67:902-12.
- Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty.Young LH, Jaffe CC, Revkin JH, McNulty PH, Cleman M. Metabolic and functional effects of perfluorocarbon distal perfusion during coronary angioplasty. The American Journal Of Cardiology 1990, 65:986-90.
- Physiologic hyperinsulinemia stimulates lactate extraction by heart muscle in the conscious dog.Young LH, Zaret BL, Barrett EJ. Physiologic hyperinsulinemia stimulates lactate extraction by heart muscle in the conscious dog. Metabolism: Clinical And Experimental 1989, 38:1115-9.
- Effect of chronic diabetes on myocardial fuel metabolism and insulin sensitivity.Barrett EJ, Schwartz RG, Young LH, Jacob R, Zaret BL. Effect of chronic diabetes on myocardial fuel metabolism and insulin sensitivity. Diabetes 1988, 37:943-8.
- Myocardial amino acid transport by canine sarcolemma vesicles.Young LH, Zaret BL, Barrett EJ. Myocardial amino acid transport by canine sarcolemma vesicles. The American Journal Of Physiology 1987, 252:H1070-6.
- An isotopic method for measurement of muscle protein synthesis and degradation in vivo.Barrett EJ, Revkin JH, Young LH, Zaret BL, Jacob R, Gelfand RA. An isotopic method for measurement of muscle protein synthesis and degradation in vivo. The Biochemical Journal 1987, 245:223-8.
- Agonist regulation of the human platelet alpha-adrenergic receptor.Cooper B, Handin RI, Young LH, Alexander RW. Agonist regulation of the human platelet alpha-adrenergic receptor. Nature 1978, 274:703-6.